BioProtect key facts
- Developer of a pro-space balloon system designed to safely and temporarily separate the rectum during prostate cancer radiation therapy.
- BioProtect’s last known valuation is $200.0M (Jan 2026).
- It has raised $67.9M; the latest was Merger/Acquisition ($200.0M) in Jan 2026.
- Notable investors include KB Investment, Innovation Authority, Peregrine Ventures, Consensus Business Group, Vincent Tchenguiz — 21 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
Who backs BioProtect
21+- ·The complete investor list: 21 names
- ·Watch BioProtect: the Monday email on marks, rounds and moves
BioProtect funding rounds
No funding rounds for BioProtect are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
BioProtect valuation
BioProtect's last known valuation is $200 million, from Jan 2026. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.
BioProtect investors
21 investors are on record for BioProtect, including KB Investment, Innovation Authority, Peregrine Ventures and Consensus Business Group.
About BioProtect
Developer of a pro-space balloon system designed to safely and temporarily separate the rectum during prostate cancer radiation therapy. The company's system acts as a spacer for the protection of healthy tissues in patients receiving radiotherapy for prostate cancer, enabling healthcare institutions to decrease the probability of serious and chronic radiation side effects while improving biochemical tumor control.
- Sector
- Healthcare
- HQ
- Tzur Yigal, Israel
- Founded
- 2004
- Employees
- 84
- Website
- bioprotect.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.
BioProtect’s last known valuation, Jan 2026. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.